Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells

T. Yamazaki, E. Wennerberg, M. Hensler, A. Buqué, J. Kraynak, J. Fucikova, XK. Zhou, B. Sveinbjørnsson, Ø. Rekdal, S. Demaria, L. Galluzzi

. 2021 ; 10 (1) : 1962592. [pub] 20210810

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003939

LTX-315 is a nonameric oncolytic peptide in early clinical development for the treatment of solid malignancies. Preclinical and clinical evidence indicates that the anticancer properties of LTX-315 originate not only from its ability to selectively kill cancer cells, but also from its capacity to promote tumor-targeting immune responses. Here, we investigated the therapeutic activity and immunological correlates of intratumoral LTX-315 administration in three syngeneic mouse models of breast carcinoma, with a focus on the identification of possible combinatorial partners. We found that breast cancer control by LTX-315 is accompanied by a reconfiguration of the immunological tumor microenvironment that supports the activation of anticancer immunity and can be boosted by radiation therapy. Mechanistically, depletion of natural killer (NK) cells compromised the capacity of LTX-315 to limit local and systemic disease progression in a mouse model of triple-negative breast cancer, and to extend the survival of mice bearing hormone-accelerated, carcinogen-driven endogenous mammary carcinomas. Altogether, our data suggest that LTX-315 controls breast cancer progression by engaging NK cell-dependent immunity.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003939
003      
CZ-PrNML
005      
20220127145713.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1080/2162402X.2021.1962592 $2 doi
035    __
$a (PubMed)34408925
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Yamazaki, Takahiro $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
245    10
$a LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells / $c T. Yamazaki, E. Wennerberg, M. Hensler, A. Buqué, J. Kraynak, J. Fucikova, XK. Zhou, B. Sveinbjørnsson, Ø. Rekdal, S. Demaria, L. Galluzzi
520    9_
$a LTX-315 is a nonameric oncolytic peptide in early clinical development for the treatment of solid malignancies. Preclinical and clinical evidence indicates that the anticancer properties of LTX-315 originate not only from its ability to selectively kill cancer cells, but also from its capacity to promote tumor-targeting immune responses. Here, we investigated the therapeutic activity and immunological correlates of intratumoral LTX-315 administration in three syngeneic mouse models of breast carcinoma, with a focus on the identification of possible combinatorial partners. We found that breast cancer control by LTX-315 is accompanied by a reconfiguration of the immunological tumor microenvironment that supports the activation of anticancer immunity and can be boosted by radiation therapy. Mechanistically, depletion of natural killer (NK) cells compromised the capacity of LTX-315 to limit local and systemic disease progression in a mouse model of triple-negative breast cancer, and to extend the survival of mice bearing hormone-accelerated, carcinogen-driven endogenous mammary carcinomas. Altogether, our data suggest that LTX-315 controls breast cancer progression by engaging NK cell-dependent immunity.
650    _2
$a zvířata $7 D000818
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $7 D007167
650    _2
$a buňky NK $7 D007694
650    _2
$a myši $7 D051379
650    12
$a oligopeptidy $7 D009842
650    12
$a triple-negativní karcinom prsu $x terapie $7 D064726
650    _2
$a nádorové mikroprostředí $7 D059016
655    _2
$a časopisecké články $7 D016428
700    1_
$a Wennerberg, Erik $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
700    1_
$a Hensler, Michal $u Sotio, Prague, Czech Republic
700    1_
$a Buqué, Aitziber $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
700    1_
$a Kraynak, Jeffrey $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
700    1_
$a Fucikova, Jitka $u Sotio, Prague, Czech Republic $u 2nd Faculty of Medicine and University Hospital Motol, Department of Immunology, Charles University, Prague, Czech Republic
700    1_
$a Zhou, Xi Kathy $u Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA
700    1_
$a Sveinbjørnsson, Baldur $u Lytix Biopharma, Oslo, Norway $u Department of Medical Biology, University of Tromsø, Tromsø, Norway $u Childhood Cancer Research Unit, Department of Women and Children Health, Karolinska Institute, Stockholm, Sweden
700    1_
$a Rekdal, Øystein $u Lytix Biopharma, Oslo, Norway $u Department of Medical Biology, University of Tromsø, Tromsø, Norway
700    1_
$a Demaria, Sandra $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA $u Sandra and Edward Meyer Cancer Center, New York, NY, USA
700    1_
$a Galluzzi, Lorenzo $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA $u Sandra and Edward Meyer Cancer Center, New York, NY, USA $u Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA
773    0_
$w MED00190079 $t Oncoimmunology $x 2162-402X $g Roč. 10, č. 1 (2021), s. 1962592
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34408925 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145710 $b ABA008
999    __
$a ok $b bmc $g 1751412 $s 1155088
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 10 $c 1 $d 1962592 $e 20210810 $i 2162-402X $m Oncoimmunology $n Oncoimmunology $x MED00190079
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace